PharmaCyte Biotech, Inc.
PMCB · XNASCIK 1157075fmd_0NBYESKYAH8YVF5KHFTX0J9KBC制造业 · 生物制品（不含诊断试剂）模板: 标准
覆盖范围: 2010年5月01日 至 2026年7月31日，共 65 个期间
| 项目 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 4 | 7 | 4 | 4 | 4 | 4 | 6 | 9 | 4 | 7 |
| 薪酬与福利 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | – | – |
| 营业利润 | (4) | (7) | (4) | (4) | (4) | (4) | (6) | (9) | (4) | (7) |
| 利息费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (0) | 0 | 0 | (0) | 0 | 0 | 2 | 9 | 35 | (13) |
| 税前利润 | – | – | – | – | – | – | – | – | 31 | (19) |
| 所得税费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | – | – | – | – | – | – | – | – | 31 | (19) |
| 净利润 | (4) | (7) | (4) | (4) | (4) | (4) | (4) | 0 | 31 | (19) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | (4) | (17) | 23 | (23) |